# US 2019/0315693 A1 · Apelin receptor (apj) agonists and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0315693 A1
- Document ID: US20190315693A1
- Status: Published application
- Kind: A1
- Application number: 16/448,976
- Filed: 2019-06-21
- Published: 2019-10-17
- Earliest claimed: 2014-06-06
- Assignees: Research Triangle Institute
- Applicants: Research Triangle Institute
- Inventors: Scott P. RUNYON; Rangan MAITRA; Sanju NARAYANAN; James Barnwell THOMAS
- Web page: https://patentgrep.com/patent/US20190315693A1

## CPC

- C07D 231/14: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- A61K 31/415: 1,2-Diazoles
- A61K 31/4155: non condensed and containing further heterocyclic rings
- A61K 31/422: not condensed and containing further heterocyclic rings
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 11/06: Antiasthmatics
- A61P 13/12: of the kidneys
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/32: Alcohol-abuse
- A61P 25/36: Opioid-abuse
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/12: Antivirals
- A61P 31/18: for HIV
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 407/12: linked by a chain containing hetero atoms as chain links
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This disclosure is directed to agonists of the apelin receptor (APJ) and uses of such agonists.

## Claims

### Claim at position 1

-29 (canceled)

### Claim 30

A compound represented by the Formula I:
or a pharmaceutically acceptable salt, a prodrug, or a salt of a prodrug,
wherein
R1 is represented by the formula:
each A is independently C1-8 alkyl, C1-8 alkyl(aryl), C1-8 alkoxy, C1-8 alkoxy aryl, C2-8 alkenyl, C3-8 alkynyl, C3-8 cycloalkyl, —CF3, —(CH2)x(NR7R8, —CN, —CONR7R8, —COR7, —CO2(CH2)xNR7R8, —CO2R7, halogen, hydroxyl, —N3, —NHCOR7, —NHSO2C1-8 alkyl, —NHCO2C1-8 alkyl, —NO2, —NR7R8, —O(CH2)x(NR7R8, —O(CH2)xCO2R7, —OCOC1-8 alkyl, —OCO(CH2)xNR7R8, —SO(1-3)R7, or —SR7;
R7 and R8 are independently alkoxy, aryl, C1-8 alkyl, C1-8 alkyl alcohol, C1-8 alkyl amino, C1-8 alkyl amido, C1-8 alkyl(aryl), C1-8 alkyl (C3-8 cycloalkyl), C1-8 alkyl guanidinyl, C1-8 alkyl heteroaryl, C1-8 alkyl imidazolyl, C1-8 alkyl indolyl, C1-8 alkyl thioether, C1-8 alkyl thiol, C2-8 alkenyl, C3-8 alkynyl, C3-8 cycloalkyl, —(CH2)xCONHR9, —(CH2)xCOR9, —(CH2)xCO2R9, H, or heteroaryl; or R7 and R8 together make a 3-8 member ring which may be substituted with one or more heteroatoms;
n is 1, 2, 3, 4 or 5;
each x is independently 0-8;
R2 is present or absent, and if present, is substituted aryl, C1-8 alkyl, C1-8 alkyl (C3-8 cycloalkyl), C3-8 cycloalkyl, or heteroaryl;
R3 is present or absent, is absent if R2 is present, and if present is aryl, C1-8 alkyl, C1-8 alkyl(aryl), C1-8 alkyl (C3-8 cycloalkyl), or C3-8 cycloalkyl;
R4, R5, and R6 are independently adamantanyl, aryl, C1-8 alkyl, C1-8 alkyl alcohol, C1-8 alkyl amino, C1-8 alkyl amido, C1-8 alkyl(aryl), C1-8 alkyl (C3-8 cycloalkyl), C1-8 alkyl (C3-8 cycloalkyl)-CO2R7, C1-8 alkyl guanidinyl, C1-8 alkyl heteroaryl, C1-8 alkyl imidazolyl, C1-8 alkyl indolyl, C1-8 alkyl thioether, C1-8 alkyl thiol, C2-8 alkenyl, C3-8 alkynyl, C3-8 cycloalkyl, C3-8 cycloalkyl-CO2R7, —(CH2)xNR7R8, —(CH2)xOR7, —(CH2)xNHCOR7, —(CH2)xNHCO2R7, —(CH2)xCONR7R8, —(CH2)xCONR7(CH2)yCO2R9, —(CH2)xCONR7(CH2)yCONR7R8, —(CH2)xCONR7(CH2)yR9, —(CH2)xCOR7, —(CH2)xCO2R7, —CHR7COR9, —CHR7CONHCHR8COR9, —CONR7R8, —CONR7(CH2)xCO2R8, —CONR7CHR8CO2R9, —CO2R9, H, or —NHCO2R7; or R4 and R5 together make a 4-8 member ring which may be substituted with one or more heteroatoms or selected from the groups comprising R6;
R9 is aryl, C1-8 alkoxy, C1-8 alkyl, C1-8 alkyl(aryl), C3-8 cycloalkyl, H, heteroaryl, or hydroxyl;
each y is independently 1-8;
and Z is H2 or ═O.

### Claim 31 (depends on 30)

The compound of claim 30, wherein n is 4; each A is independently C1-4 alkoxy, C1-4 alkoxy aryl, or halogen;
R2 is substituted aryl, C1-8 alkyl or C3-8 cycloalkyl;
R4 is C1-8 alkyl, C1-8 alkyl(aryl), C1-8 alkyl (C3-8 cycloalkyl) or CO2R9; R5 is —(CH2)xCNHCOR7, —(CH2)xCNHCO2R7, —(CH2)xCONR7R8, —(CH2)xCONR7(CH2)yCO2R9, —(CH2)xCONR7(CH2)yCONR7R8, —(CH2)xCONR7(CH2)yR9, —(CH2)xCOR7, —(CH2)xCO2R7, —CHR7COR9, —CHR7CONHCHR8COR9, —CONR7R8, —CONR7(CH2)xCO2R8, or —CO2R9; R6 is H;
R9 is C1-8 alkyl, H, or heteroaryl which is an oxazole;
x is 1-4;
y is 1-3; and
Z is ═O.

### Claim 32 (depends on 31)

The compound of claim 31, wherein n is 4; each A is independently C1 alkoxy, C1 alkoxy aryl, or halogen;
R2 is substituted aryl, C4 alkyl or C6 cycloalkyl;
R4 is C1-4 alkyl, C1-8 alkyl(aryl), C1-8 alkyl (C3-8 cycloalkyl) or —CO2R9; R5 is —(CH2)xCNHCOR7, —(CH2)xCNHCO2R7, —(CH2)xCONR7R8, —(CH2)xCONR7(CH2)yCO2R9, —(CH2)xCONR7(CH2)yCONR7R8, —(CH2)xCONR7(CH2)yR9, —(CH2)xCOR7, —(CH2)xCO2R7, —CHR7COR9, —CHR7CONHCHR8COR9, —CONR7R8, —CONR7(CH2)xCO2R8, or —CO2R9; R6 is H; R8 is C1-4 alkyl or H;
R9 is C1-8 alkyl, H, or heteroaryl which is an oxazole;
x is 1-4;
y is 1-3; and
Z is ═O.

### Claim 33 (depends on 32)

The compound of claim 32, wherein n is 4; each A is independently C1 alkoxy, C1 alkoxy aryl, or fluorine;
R2 is substituted aryl, C4 alkyl or C6 cycloalkyl;
R4 is C1-4 alkyl, C1-4 alkyl(aryl), C1-4 alkyl (C5-8 cycloalkyl) or —CO2R9; R5 is —(CH2)xCNHCOR7, —(CH2)xCNHCO2R7, —(CH2)xCONR7R8, —(CH2)xCONR7(CH2)yCO2R9, —(CH2)xCONR7(CH2)yCONR7R8, —(CH2)xCONR7(CH2)yR9, —(CH2)xCOR7, —(CH2)xCO2R7, —CHR7COR9, —CHR7CONHCHR8COR9, —CONR7R8, —CONR7(CH2)xCO2R8, or —CO2R9; R6 is H; R8 is C1-4 alkyl or H;
R9 is C1-8 alkyl, H, or heteroaryl which is an oxazole;
x is 1-4; and
y is 1-3.

### Claim 34 (depends on 33)

The compound of claim 33, wherein n is 4; each A is independently C1 alkoxy, C1 alkoxy aryl, or fluorine;
R2 is substituted aryl, C4 alkyl, or C6 cycloalkyl;
R4 is C1-4 alkyl, C1-4 alkyl(aryl), C1-4 alkyl (C5-8 cycloalkyl) or —CO2R9; R5 is —(CH2)xCNHCOR7, —(CH2)xCNHCO2R7, —(CH2)xCONR7R8, —(CH2)xCONR7(CH2)yCO2R9, —(CH2)xCONR7(CH2)yCONR7R8, —(CH2)xCONR7(CH2)yR9, —(CH2)xCOR7, —(CH2)xCO2R7, —CHR7COR9, —CHR7CONHCHR8COR9, —CONR7R8, —CONR7(CH2)xCO2R8, or —CO2R9; R6 is H; R8 is H;
R9 is C1-8 alkyl, H, or heteroaryl which is an oxazole;
x is 1-4; and
y is 1-3.

### Claim 35 (depends on 30)

The compound of claim 30, wherein n is 2; each A is independently C1-4 alkoxy, C1-4 alkoxy aryl;
R2 is substituted aryl, C1-8 alkyl or C3-8 cycloalkyl;
R4 is C1-8 alkyl, C1-8 alkyl(aryl), C1-8 alkyl (C3-8 cycloalkyl) or CO2R9; R5 is —(CH2)xCNHCOR7, —(CH2)xCNHCO2R7, —(CH2)xCONR7R8, —(CH2)xCONR7(CH2)yCO2R9, —(CH2)xCONR7(CH2)yCONR7R8, —(CH2)xCONR7(CH2)yR9, —(CH2)xCOR7, —(CH2)xCO2R7, —CHR7COR9, —CHR7CONHCHR8COR9, —CONR7R8, —CONR7(CH2)xCO2R8, or CO2R9; R6 is H;
R9 is C1-8 alkyl, H, or heteroaryl which is an oxazole;
x is 1-4;
y is 1-3; and
Z is ═O.

### Claim 36 (depends on 35)

The compound of claim 35, wherein n is 2; each A is independently C1 alkoxy, C1 alkoxy aryl;
R2 is substituted aryl, C4 alkyl or C6 cycloalkyl;
R4 is C1-8 alkyl, C1-8 alkyl(aryl), C1-8 alkyl (C3-8 cycloalkyl) or —CO2R9; R5 is —(CH2)xCNHCOR7, —(CH2)xCNHCO2R7, —(CH2)xCONR7R8, —(CH2)xCONR7(CH2)yCO2R9, —(CH2)xCONR7(CH2)yCONR7R8, —(CH2)xCONR7(CH2)yR9, —(CH2)xCOR7, —(CH2)xCO2R7, —CHR7COR9, —CHR7CONHCHR8COR9, —CONR7R8, —CONR7(CH2)xCO2R8, or —CO2R9; R6 is H; R8 is C1-4 alkyl or H;
R9 is C1-8 alkyl, H, or heteroaryl which is an oxazole;
x is 1-4;
y is 1-3; and
Z is ═O.

### Claim 37 (depends on 36)

The compound of claim 36, wherein n is 2; each A is independently C1 alkoxy, C1 alkoxy aryl;
R2 is substituted aryl, C4 alkyl or C6 cycloalkyl;
R4 is C1-4 alkyl, C1-4 alkyl(aryl), C1-4 alkyl (C5-8 cycloalkyl) or —CO2R9; R5 is —(CH2)xCNHCOR7, —(CH2)xCNHCO2R7, —(CH2)xCONR7R8, —(CH2)xCONR7(CH2)yCO2R9, —(CH2)xCONR7(CH2)yCONR7R8, —(CH2)xCONR7(CH2)yR9, —(CH2)xCOR7, —(CH2)xCO2R7, —CHR7COR9, —CHR7CONHCHR8COR9, —CONR7R8, —CONR7(CH2)xCO2R8, or —CO2R9; R6 is H; R8 is C1-4 alkyl or H;
R9 is C1-8 alkyl, H, or heteroaryl which is an oxazole;
x is 1-4;
y is 1-3; and
Z is ═O.

### Claim 38 (depends on 37)

The compound of claim 37, wherein n is 2; each A is independently C1 alkoxy, C1 alkoxy aryl;
R2 is substituted aryl, C4 alkyl or C6 cycloalkyl;
R4 is C1-4 alkyl, C1-4 alkyl(aryl), C1-4 alkyl (C5-8 cycloalkyl) or —CO2R9; R5 is —(CH2)xCNHCOR7, —(CH2)xCNHCO2R7, —(CH2)xCONR7R8, —(CH2)xCONR7(CH2)yCO2R9, —(CH2)xCONR7(CH2)yCONR7R8, —(CH2)xCONR7(CH2)yR9, —(CH2)xCOR7, —(CH2)xCO2R7, —CHR7COR9, —CHR7CONHCHR8COR9, —CONR7R8, —CONR7(CH2)xCO2R8, or —CO2R9; R6 is H; R8 is H;
R9 is C1-8 alkyl, H, or heteroaryl which is an oxazole;
x is 1-4;
y is 1-3; and
Z is ═O.

### Claim 39 (depends on 30)

The compound of claim 30, wherein R4, R5, or R6 are C1-8 alkyl heteroaryl and the C1-8 alkyl heteroaryl is a C1-8 alkyl tetrazole.

### Claim 40 (depends on 1)

The compound of claim 1 having the structure of any of compounds 34, 34P, 56, 65, 67, 70, 71, 77, 79, 81, 82, 86, 93, 95, 103, 118, 126, 127, 129, 130, 132, 133, 134, 136, 137, 138, 140, 141, 142, 143, 153, 154, 155, 156, 157, 161, 162, 163, 164, 167, 168, 169, 171, 172, 173, 174, 175, 176, 181, 182, 183, 184, 185, 186, 187, 188, 189, 191, 198, 204, 205, 212, 213, 214, 215, 217, 218, 219, 220, 225, 226, 228, 229, 231, 232, 233, 234, 235, 236, 238, 239, 240, 241, 242, 245, 247, 249, 251, 252, 253, 256, 257, 258, 259, 263, and 265, as set forth in Table 1.

### Claim 41 (depends on 30)

A pharmaceutical composition comprising at least one pharmaceutically acceptable excipient and a therapeutically effective amount of the compound of claim 30.

### Claim 42 (depends on 41)

The pharmaceutical composition of claim 41, wherein the therapeutically effective amount is an amount effective for lowering blood pressure.

### Claim 43 (depends on 41)

The pharmaceutical composition of claim 41, wherein the therapeutically effective amount is an amount effective for the treatment of asthma, cardiomyopathy, diabetes, dyslipidemia, hypertension, inflammation, liver disease, metabolic disorder, neurodegenerative disease, obesity, preeclampsia, or renal dysfunction.

### Claim 44 (depends on 43)

The pharmaceutical composition of claim 43, wherein the hypertension is pulmonary arterial hypertension.

### Claim 45 (depends on 43)

The pharmaceutical composition of claim 43, wherein the liver disease is alcoholic liver disease, toxicant-induced liver disease, or viral-induced liver disease.

### Claim 46 (depends on 43)

The pharmaceutical composition of claim 43, wherein the renal dysfunction is polycystic kidney disease.

### Claim 47 (depends on 41)

The pharmaceutical composition of claim 41, wherein the therapeutically effective amount is an amount effective to treat a vein-related disorder.

### Claim 48 (depends on 47)

The pharmaceutical composition of claim 47, wherein the therapeutically effective amount is an amount effective to treat an angioma, a venous insufficiency, a stasis or a thrombosis.

### Claim 49 (depends on 41)

The pharmaceutical composition of claim 41, wherein the therapeutically effective amount is an amount effective to reduce the likelihood of HIV-related neurodegeneration.

### Claim 50 (depends on 30)

A method of treatment of an apelin (APJ) related disorder comprising administration of the compound of claim 30.

### Claim 51 (depends on 50)

The method of claim 50, wherein the apelin receptor (APJ) related disorder is asthma, cardiomyopathy, diabetes, dyslipidemia, hypertension, inflammation, liver disease, metabolic disorder, neurodegenerative disease, obesity, preeclampsia, or renal dysfunction.

### Claim 52 (depends on 51)

The method of claim 51, wherein the hypertension is a pulmonary arterial hypertension.

### Claim 53 (depends on 51)

The method of claim 51, wherein the liver disease is an alcoholic liver disease, a toxicant-induced liver disease or a viral-induced liver disease.

### Claim 54 (depends on 51)

The method of claim 51, wherein the renal dysfunction is a polycystic kidney disease.

### Claim 55 (depends on 50)

The method claim 50, further comprising an α-blocker, an angiotensin converting enzyme (ACE) inhibitor, an angiotensin-receptor blocker (ARB), a β-blocker, a calcium channel blocker, or a diuretic for the treatment of the apelin receptor (APJ) related disorder.

### Claim 56 (depends on 30)

A method for treatment of a vein-related disorder comprising administration of a compound of claim 30.

### Claim 57 (depends on 56)

The method of claim 56, wherein the vein-related disorder is an angioma, a venous insufficiency, a stasis or a thrombosis.

### Claim 58 (depends on 30)

A method for treatment to reduce the likelihood of HIV-related neurodegeneration comprising administration of the compound of claim 30.
